These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16368722)

  • 1. The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns.
    Wooltorton E
    CMAJ; 2006 Jan; 174(2):164-5. PubMed ID: 16368722
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetic overview of Ortho Evra/Evra.
    Abrams LS; Skee D; Natarajan J; Wong FA
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S3-12. PubMed ID: 11849630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormonal contraceptive patch].
    Lidegaard O
    Ugeskr Laeger; 2004 Oct; 166(41):3591. PubMed ID: 15515462
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise.
    Abrams LS; Skee DM; Natarajan J; Wong FA; Leese PT; Creasy GW; Shangold MM
    J Clin Pharmacol; 2001 Dec; 41(12):1301-9. PubMed ID: 11762557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How should we advise patients about the contraceptive patch, given the FDA warning?
    Thacker HL; Falcone T; Atreja A; Jain A; Harris CM
    Cleve Clin J Med; 2006 Jan; 73(1):45-7. PubMed ID: 16444915
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.
    Abrams LS; Skee DM; Wong FA; Anderson NJ; Leese PT
    J Clin Pharmacol; 2001 Nov; 41(11):1232-7. PubMed ID: 11697756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
    Bifano M; Sevinsky H; Hwang C; Kandoussi H; Jiang H; Grasela D; Bertz R
    Antivir Ther; 2014; 19(5):511-9. PubMed ID: 24343001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transdermal contraception.
    Creasy GW; Abrams LS; Fisher AC
    Semin Reprod Med; 2001 Dec; 19(4):373-80. PubMed ID: 11727179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.
    Goa KL; Warner GT; Easthope SE
    Treat Endocrinol; 2003; 2(3):191-206. PubMed ID: 15966567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites.
    Abrams LS; Skee DM; Natarajan J; Wong FA; Anderson GD
    Br J Clin Pharmacol; 2002 Feb; 53(2):141-6. PubMed ID: 11851637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.
    Devineni D; Skee D; Vaccaro N; Massarella J; Janssens L; LaGuardia KD; Leung AT
    J Clin Pharmacol; 2007 Apr; 47(4):497-509. PubMed ID: 17389559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evra--a patch on oral contraception?
    Drug Ther Bull; 2003 Dec; 41(12):89-91. PubMed ID: 14723093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Transdermal contraception--a new beginning].
    Sigridov I; Dikov I; Ivanov S
    Akush Ginekol (Sofiia); 2004; 43 Suppl 1():19-27. PubMed ID: 15323313
    [No Abstract]   [Full Text] [Related]  

  • 14. The introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra).
    Zieman M
    Fertil Steril; 2002 Feb; 77(2 Suppl 2):S1-2. PubMed ID: 11849629
    [No Abstract]   [Full Text] [Related]  

  • 15. New warning on birth control patch.
    FDA Consum; 2006; 40(1):4. PubMed ID: 16532540
    [No Abstract]   [Full Text] [Related]  

  • 16. The transdermal contraceptive patch: a new approach to hormonal contraception.
    Burkman RT
    Int J Fertil Womens Med; 2002; 47(2):69-76. PubMed ID: 11991433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety evaluation of a transdermal contraceptive system with an oral contraceptive].
    Radowicki S; Skórzewska K; Szlendak K
    Ginekol Pol; 2005 Nov; 76(11):884-9. PubMed ID: 16566363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A transdermal form of combined hormonal contraceptives (EVRA)].
    Fanta M
    Ceska Gynekol; 2003 Oct; 68(5):341-5. PubMed ID: 14692356
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra).
    Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit
    J Fam Plann Reprod Health Care; 2004 Jan; 30(1):43-5. PubMed ID: 15006313
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of norelgestromin in rabbit plasma by LC-MS/MS and its application to the pharmacokinetic study of ORTHO EVRA.
    Liu X; Ding C; Ge Q; Zhi X; Zhou Z
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jan; 877(3):311-5. PubMed ID: 19097950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.